phiopharma.com (PHIO) Company Cash on Hand

Phio Pharmaceuticals (PHIO) is optimizing its RNA component supply chains, mitigating risks through a global network of research centers. The company is developing RNA interference methods to combat skin cancer, while strict FDA regulations dictate the pace of its clinical base expansion. The company's cash position illustrates current liquidity, with 0.01 showing the current value of the metric for financial stability analysis.
Analytical breakdowns for Phio Pharmaceuticals

This indicator aggregates liquid assets on accounts, reflecting the fundamental stability and the ability of Phio Pharmaceuticals to sustain operational activities without external borrowing. By analyzing the cash on hand metric, an investor assesses the financing efficiency of RNA component supply chains and the diversification of Phio Pharmaceuticals research bases, where excessive growth in balances may signal stagnation in capital expenditures for therapy development.